Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain
Oral transmucosal fentanyl citrate for the management of breakthrough pain
The time-weighted consumption of epidural local anaesthetic from the time of induction of the CSE to the time of delivery, including local anaesthetic used to treat breakthrough pain
, was similar for the CIPCEA group (mean [SD] 9.
is episodic or transient pain that occurs despite stable pain management in patients receiving chronic opioid therapy (Payne, 2006; Portenoy & Hagen 1990 ).
as Fentora, was approved in 2006 for treating breakthrough pain
in patients with cancer who are already on around-the-clock opioid therapy.
Approximately 40% of cancer patients live with breakthrough pain
on a daily basis.
He takes an average of 2 doses per day of hydrocodone, 5 mg, for breakthrough pain
FENTORA is currently approved by the FDA for the management of breakthrough pain
in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
With its earlier Phase I SBIR grant, Javelin conducted a successful pilot study of intranasal ketamine to control breakthrough pain
in 20 patients.
Buccal and rapid disintegration oral formulations will see much faster gains due to onset-of-action and ingestion advantages, but will only penetrate a limited range of high value-added applications such as breakthrough pain
control and the treatment of patients with swallowing difficulties.
It's not uncommon for such breakthrough pain
to arise from a mild touch to a person's skin.
6 million cancer patients experiencing breakthrough pain
in the seven major markets in 2011.